The company is the only biopharma focused exclusively on the development and commercialisation of new treatment options for people with hemophilia.
Butler has more than 20 years experience in the field of commercialisation for innovative therapies.
He replaces Michael Griffith, who will become chief scientific officer, and will remain as president at Inspiration.
UCB has more than drugs in its 2015 pipeline, while BUPA and biotechs hire new recruits.
Simon Sturge leaves Boehringer Ingelheim to head Merck's biosimilars unit, as well as the European Medicines Agency,...
All change at biopharmas this week, as we reveal the industry movers at four biologics firms. Plus,...
Changes at Novo Nordisk, Questcor, Nicox and more in this week's column.
This week's People on the Move column sees leadership appointments at two major trade bodies, as well...